ES2699447T3 - Citrato férrico para revertir, prevenir, retrasar o estabilizar la calcificación de tejidos blandos - Google Patents

Citrato férrico para revertir, prevenir, retrasar o estabilizar la calcificación de tejidos blandos Download PDF

Info

Publication number
ES2699447T3
ES2699447T3 ES07762833T ES07762833T ES2699447T3 ES 2699447 T3 ES2699447 T3 ES 2699447T3 ES 07762833 T ES07762833 T ES 07762833T ES 07762833 T ES07762833 T ES 07762833T ES 2699447 T3 ES2699447 T3 ES 2699447T3
Authority
ES
Spain
Prior art keywords
ferric citrate
ferric
calcification
patients
citrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07762833T
Other languages
English (en)
Spanish (es)
Inventor
Keith Chan
Winston Town
Shou Shan Chiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panion and BF Biotech Inc
Original Assignee
Panion and BF Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2699447(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/032385 external-priority patent/WO2007022435A2/en
Application filed by Panion and BF Biotech Inc filed Critical Panion and BF Biotech Inc
Application granted granted Critical
Publication of ES2699447T3 publication Critical patent/ES2699447T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ES07762833T 2006-01-30 2007-01-26 Citrato férrico para revertir, prevenir, retrasar o estabilizar la calcificación de tejidos blandos Active ES2699447T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76325306P 2006-01-30 2006-01-30
PCT/US2006/032385 WO2007022435A2 (en) 2005-08-18 2006-08-18 Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
PCT/US2007/002157 WO2007089577A2 (en) 2006-01-30 2007-01-26 Method of reversing, preventing, delaying or stabilizing soft tissue calcification

Publications (1)

Publication Number Publication Date
ES2699447T3 true ES2699447T3 (es) 2019-02-11

Family

ID=39739742

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07762833T Active ES2699447T3 (es) 2006-01-30 2007-01-26 Citrato férrico para revertir, prevenir, retrasar o estabilizar la calcificación de tejidos blandos
ES07717051.2T Active ES2580127T3 (es) 2006-01-30 2007-01-26 Procedimiento de tratamiento de la nefropatía crónica

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07717051.2T Active ES2580127T3 (es) 2006-01-30 2007-01-26 Procedimiento de tratamiento de la nefropatía crónica

Country Status (11)

Country Link
US (8) US20090186939A1 (cg-RX-API-DMAC7.html)
EP (3) EP1978808B1 (cg-RX-API-DMAC7.html)
JP (14) JP2009525276A (cg-RX-API-DMAC7.html)
CN (4) CN105616397A (cg-RX-API-DMAC7.html)
AU (2) AU2007210096B2 (cg-RX-API-DMAC7.html)
CA (2) CA2640763C (cg-RX-API-DMAC7.html)
DK (1) DK1978807T3 (cg-RX-API-DMAC7.html)
ES (2) ES2699447T3 (cg-RX-API-DMAC7.html)
HU (1) HUE028029T2 (cg-RX-API-DMAC7.html)
IL (2) IL192545A (cg-RX-API-DMAC7.html)
WO (2) WO2007089571A2 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
US20220144872A1 (en) * 2003-02-19 2022-05-12 Panion & Bf Biotech Inc. Pharmaceutical-Grade Ferric Organic Compounds, Uses Thereof and Methods of Making Same
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
EP1978808B1 (en) * 2006-01-30 2018-08-29 Panion & BF Biotech Inc. Ferric citrate for reversing, preventing, delaying or stabilizing soft tissue calcification
US7658952B2 (en) 2007-10-11 2010-02-09 Baxter International Inc. Dialysis solutions containing pyrophosphates
KR101322259B1 (ko) 2008-10-27 2013-10-28 에스비아이 파마 가부시키가이샤 5-아미노레불린산 혹은 그의 유도체, 또는 그들 염을 유효성분으로 하는 성인병의 예방·개선제
KR20120046753A (ko) * 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
US8178709B2 (en) 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
WO2012005340A1 (ja) * 2010-07-07 2012-01-12 日本たばこ産業株式会社 クエン酸第二鉄を含む錠剤
JP2012112785A (ja) * 2010-11-24 2012-06-14 Tohoku Univ 透析膜の評価方法
MY171864A (en) * 2011-01-18 2019-11-05 Japan Tobacco Inc Iron(iii) citrate, substantially free of beta-iron hydroxide oxide
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients
CA2884062C (en) * 2012-09-04 2021-04-20 Charles Y.C. Pak Citrate-rich calcium-magnesium supplement and uses thereof
CN105873583A (zh) * 2013-11-04 2016-08-17 凯克斯生物制药公司 用于降低慢性肾病患者的心力衰竭的枸橼酸铁
EP3157516A4 (en) * 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
US20180222836A1 (en) * 2015-08-05 2018-08-09 Lupin Limited Process for the Preparation of Pharmaceutical Grade Ferric Citrate
JP7219898B2 (ja) * 2017-04-18 2023-02-09 国立大学法人東北大学 アルカリ性化剤による血液浄化
WO2018193648A1 (ja) * 2017-04-18 2018-10-25 国立大学法人東北大学 アルカリ性化剤による血液浄化
JP7578234B2 (ja) * 2017-04-18 2024-11-06 国立大学法人東北大学 アルカリ性化剤による血液浄化
IT201700085412A1 (it) * 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
IT201700089258A1 (it) 2017-08-02 2019-02-02 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di carenza di ferro
JP7364572B2 (ja) 2018-01-12 2023-10-18 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 流体中のアンモニア及びアンモニウムの検出及び定量のためのシステム及び方法
US20210267959A1 (en) * 2018-07-17 2021-09-02 The Regents Of The University Of California Methods of treating renal disease
CN113164422A (zh) * 2018-10-17 2021-07-23 京都府公立大学法人 糖尿病肾病中的肾纤维化抑制剂
US12324793B2 (en) 2018-10-17 2025-06-10 Tohoku University Method for renal protection
EP3964264A4 (en) * 2019-04-28 2023-07-12 Tohoku University NOVEL PHARMACEUTICAL COMPOSITION
IT201900007329A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati per uso nel trattamento della mucosa gastrica, diabete e alti livelli di glicemia
IT201900007326A1 (it) 2019-05-27 2020-11-27 Alesco Srl Composizioni comprendenti acidi grassi cetilati e loro uso nel trattamento di artriti e stati infiammatori articolari
IT201900007311A1 (it) 2019-05-27 2020-11-27 Alesco Srl Procedimento per la preparazione di una composizione comprendente acidi grassi cetilati
EP4149773B1 (fr) * 2020-05-13 2024-10-02 Compagnie Generale Des Etablissements Michelin Pneumatique a adherence sur sol mouille amelioree en fin de vie
AU2022227671A1 (en) * 2021-02-24 2023-09-07 MoxxiTech, LLC Compositions and methods for treating canine parvovirus infection
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
KR102623739B1 (ko) * 2022-07-28 2024-01-11 주식회사 페라메드 시트르산과 철을 포함하는 착화합물 및 그를 포함하는 식품 조성물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2081547A (en) 1934-02-14 1937-05-25 Parke Davis & Co Therapeutic agent
DE1131360B (de) 1957-11-26 1962-06-14 Vitarine Company Inc Verfahren zum Stabilisieren von waessrigen Loesungen, die neben Vitamin B noch Vitamin B und Vitamin C enthalten
SU142643A1 (ru) 1961-03-25 1961-11-30 В.Б. Тихомиров Способ извлечени соединений железа из водной фазы
AT279048B (de) 1967-07-04 1970-02-25 Pharmazeutische Fabrik Montavit Gmbh Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon
US3549614A (en) 1967-07-13 1970-12-22 Jan Zbigniew Mioduszewski Method of manufacture of mixed complex compounds of ferric iron with hydrogenated dextran and citric acid or sodium citrate
GB1224589A (en) 1969-10-06 1971-03-10 Gerhard Gergely Complex iron salts
US4180567A (en) * 1977-09-02 1979-12-25 Pharmachem Corporation Iron preparations and methods of making and administering the same
DE3228231A1 (de) 1982-07-28 1984-02-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München Arzneimittel, calciummischsalze von polymeren, anionischen carbonsaeuren und/oder schwefelsaeureestern, verfahren zu ihrer herstellung und ihre verwendung
US5089644A (en) 1985-01-04 1992-02-18 Salutar Inc. Preparation of oxamine complexes
US4851221A (en) 1985-02-19 1989-07-25 Mission Pharmacal Company Liquid calcium supplementation from readily soluble mixtures of calcium compound and citric acid
IT1222654B (it) 1987-09-14 1990-09-12 Schering Ag Complesso micellare di ferro-citrato
GB2212396A (en) 1987-12-18 1989-07-26 Procter & Gamble Dietary supplement comprising calcium and delayed release coated iron
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
NL194959C (nl) 1988-10-04 2003-09-02 Otsuka Pharma Co Ltd Preparaat voor het toedienen van ijzer.
CA2046592C (en) 1989-02-17 2000-05-02 Aws Nashef Calcification mitigation of bioprosthetic implants
US4970079A (en) 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
JP2523057B2 (ja) 1990-10-31 1996-08-07 有限会社丸吉商事 多重ポリ袋の製造方法及び製造装置
DE4239442C2 (de) 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
JP3302178B2 (ja) 1994-06-22 2002-07-15 日本クラウンコルク株式会社 合成樹脂製容器蓋
JPH08198760A (ja) 1995-01-20 1996-08-06 Japan Organo Co Ltd 経口用リン酸イオン吸着剤
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
DE19638044A1 (de) 1996-09-18 1998-03-19 Bayer Ag Immunogene Peptide von Maul- und Klauenseuchen-Viren
US5753706A (en) 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
RU2188033C2 (ru) 1997-03-18 2002-08-27 Рош Диагностикс Гмбх Комбинированные фармацевтические препараты, содержащие эритропоэтин и препараты железа
US6254635B1 (en) * 1998-02-02 2001-07-03 St. Jude Medical, Inc. Calcification-resistant medical articles
US6706287B2 (en) * 2001-05-15 2004-03-16 Kibow Biotech Inc. Prebiotic and probiotic compositions and methods for their use in gut-based therapies
CN1315174A (zh) 2000-03-31 2001-10-03 苏荣仁 治疗肾衰的药物组合物
US6887897B2 (en) * 2001-07-31 2005-05-03 Mission Pharmacal Company Calcium glutarate supplement and phosphorus binder
CA2492035A1 (en) 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
CN1202067C (zh) * 2002-09-09 2005-05-18 苏荣仁 药用级枸橼酸铁的制备方法
US8093423B2 (en) * 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
KR100511227B1 (ko) 2003-06-27 2005-08-31 박상래 휴대용 감시 카메라 및 이를 이용한 개인 방범 시스템
TWI259772B (en) 2003-09-04 2006-08-11 Panion & Bf Biotech Inc Medical composition comprising ferric citrate, ferric citrate in medical grade and preparation thereof, and dietary nutriment comprising ferric citrate
CN1600302A (zh) 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
US6903235B2 (en) * 2003-10-08 2005-06-07 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric citrate
MX2007001114A (es) * 2004-07-27 2007-07-11 Shire Pharmaceuticals Inc Metodo para tratar hiperfosfatemia usando hidroxicarbonato de lantano.
US7733285B2 (en) * 2005-05-18 2010-06-08 Qualcomm Incorporated Integrated, closely spaced, high isolation, printed dipoles
US7904971B2 (en) * 2005-05-19 2011-03-15 Mine Safety Appliances Company Protective padding and protective padding systems
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
JP4692234B2 (ja) 2005-11-10 2011-06-01 ソニー株式会社 変調テーブル、変調装置および方法、プログラム、並びに記録媒体
US7682811B2 (en) 2006-01-27 2010-03-23 University Of Massachusetts Systems and methods for producing biofuels and related materials
KR20080094013A (ko) 2006-01-30 2008-10-22 글로보아시아 엘엘씨 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법
EP1978808B1 (en) 2006-01-30 2018-08-29 Panion & BF Biotech Inc. Ferric citrate for reversing, preventing, delaying or stabilizing soft tissue calcification
CN101019848B (zh) 2006-11-17 2010-09-15 苏荣仁 枸橼酸铁在制备防治血管钙化的药物中的应用
WO2008147153A1 (en) 2007-05-31 2008-12-04 Lg Chem, Ltd. Electrical connecting member of assembling type and secondary battery pack containing the same
JP5526466B2 (ja) 2007-07-17 2014-06-18 株式会社大林組 耐火セグメントの製造方法
CN101235186B (zh) 2008-01-03 2010-08-11 中国船舶重工集团公司第七二五研究所 一种无溶剂可自分层固化的环氧-有机硅组合物
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태

Also Published As

Publication number Publication date
JP2018109001A (ja) 2018-07-12
EP1978808A2 (en) 2008-10-15
CN101374416A (zh) 2009-02-25
IL193099A0 (en) 2009-02-11
JP2017095477A (ja) 2017-06-01
HUE028029T2 (en) 2016-11-28
US10898459B2 (en) 2021-01-26
CA2640763A1 (en) 2007-08-09
WO2007089571A3 (en) 2008-01-24
JP2017125048A (ja) 2017-07-20
IL193099A (en) 2016-04-21
CN105055446A (zh) 2015-11-18
AU2007210096A1 (en) 2007-08-09
US20250144065A1 (en) 2025-05-08
WO2007089571A2 (en) 2007-08-09
US20090186939A1 (en) 2009-07-23
JP2025016448A (ja) 2025-02-04
WO2007089571A8 (en) 2008-11-06
EP1978807A2 (en) 2008-10-15
US20180235923A1 (en) 2018-08-23
CA2640763C (en) 2016-10-11
ES2580127T3 (es) 2016-08-19
JP6368186B2 (ja) 2018-08-01
JP2016026177A (ja) 2016-02-12
US20110060041A1 (en) 2011-03-10
JP2013227333A (ja) 2013-11-07
EP3066923A2 (en) 2016-09-14
US20220193022A1 (en) 2022-06-23
EP1978807A4 (en) 2012-05-16
CA2640974C (en) 2020-04-28
JP2014240405A (ja) 2014-12-25
EP3066923A3 (en) 2016-10-19
IL192545A0 (en) 2009-08-03
JP2013231057A (ja) 2013-11-14
DK1978807T3 (en) 2016-07-04
JP2022020633A (ja) 2022-02-01
US20180133191A1 (en) 2018-05-17
WO2007089577A2 (en) 2007-08-09
WO2007089577A3 (en) 2008-02-21
JP6154226B2 (ja) 2017-06-28
AU2007210096B2 (en) 2013-10-24
US20170368016A1 (en) 2017-12-28
US9750715B2 (en) 2017-09-05
CN105055446B (zh) 2022-06-03
EP1978808A4 (en) 2012-05-16
JP2009525276A (ja) 2009-07-09
JP2017036289A (ja) 2017-02-16
AU2007210090B2 (en) 2013-08-22
JP2019194212A (ja) 2019-11-07
CN101378658A (zh) 2009-03-04
IL192545A (en) 2015-08-31
AU2007210090A1 (en) 2007-08-09
EP1978808B1 (en) 2018-08-29
CN105616397A (zh) 2016-06-01
US20090326060A1 (en) 2009-12-31
JP6632842B2 (ja) 2020-01-22
EP3066923B1 (en) 2025-11-05
US9889113B2 (en) 2018-02-13
CA2640974A1 (en) 2007-08-09
JP2023055886A (ja) 2023-04-18
EP1978807B1 (en) 2016-03-23
JP6239169B2 (ja) 2017-11-29
JP2009525277A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
US9889113B2 (en) Method for reversing, preventing, delaying or stabilizing soft tissue calcification
RU2700927C2 (ru) Офтальмологическая композиция, содержащая циклоспорин и трегалозу
ES2847883T3 (es) Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares
CN107362157A (zh) 用于医学和兽医学的眼科药物组合物
EA032779B1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
ES2772724T3 (es) Composición farmacéutica para la prevención y el tratamiento de enfermedades del ojo seco, que contiene imatinib como principio activo
Waszczykowska et al. Effect of treatment with silver (I) complex of metronidazole on ocular rosacea: Design and formulation of new silver drug with potent antimicrobial activity
JP6820658B2 (ja) ジピリダモールを用いる眼疾患の治療において使用するための組成物
KR20080094013A (ko) 연조직의 석회화 역전, 예방, 지연 또는 안정화 방법
KR20150032552A (ko) 치료 제제 및 치료 방법
JP7850475B2 (ja) レコフラボン(recoflavone)を含む眼球乾燥症を処置するための点眼組成物
ES2860767T3 (es) Mirabegrón para el tratamiento de enfermedades retinianas
JP5713791B2 (ja) 眼科用剤
ES2268452T3 (es) Agente con efecto destructivo en tumores malignos asi como procedimiento para su produccion.
AU2016298794A1 (en) Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions, and methods for producing same
JP6811983B2 (ja) 網膜神経節細胞死抑制活性を有する経口用組成物
US20110288101A1 (en) Surgical compositions containing sigma-receptor agonists
JP7197112B2 (ja) 水泡性角膜症治療用医薬組成物
IT202300017430A1 (it) Soluzione oftalmica in forma di collirio contenente una isoforma umana ricombinante di manganese superossido dismutasi (rmnsod) per la cura di patologie dell’occhio
CN107970211A (zh) 术前眼角膜冲洗液、制备方法及其应用
JP2024528234A (ja) レコフラボン(recoflavone)を含有するドライアイ症候群を処置するための点眼組成物及びそれを製造するための方法
JPH0625062B2 (ja) ステロイド白内障予防治療薬
Davidson tive. Ray K. Daily
WO2017182620A2 (en) Ophthalmic dye composition